Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward.

Authors
Category Primary study
JournalEuropean urology oncology
Year 2025
Recent results from IMvigor 011 constitute the first prospective, randomized validation of a therapeutic strategy guided by circulating tumor DNA (ctDNA) status in urothelial cancer. We discuss the promise of ctDNA for guiding treatment decisions in this setting and highlight the pitfalls and further work required for wider implementation of ctDNA-based strategies.
Epistemonikos ID: 7db27785b9e6ddf850c24fd247d3150394e55065
First added on: Nov 20, 2025